Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients
- 1 March 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Psychiatry
- Vol. 19 (2), 151-157
- https://doi.org/10.1097/01.yco.0000214340.14131.bd
Abstract
Current treatments for schizophrenia target the dopamine system. Developments of new treatments that target the glutamate system, however, are under progress, in particular, for the N-methyl-D-aspartate-type glutamate receptor. Compared with dopaminergic treatments, these treatments may show improved efficacy in the treatment of persistent negative symptoms. During the past year, clinical trials have been published with several agonists at the glycine site of the N-methyl-D-aspartate receptor, including glycine, D-serine, D-alanine and with the glycine transport inhibitor, sarcosine. Studies published during the past year indicate highly significant beneficial effects on negative symptoms when these compounds are added to both conventional and newer atypical antipsychotics in efficacy models although an effectiveness trial of current formulations of glycine and D-cycloserine failed to show an overall benefit. Relevant issues across studies may include the compound chosen, its formulation and tolerability, populations studied, and the nature and dose of the base antipsychotic treatment. The present findings continue to support the use of N-methyl-D-aspartate/glycine site agonists as potential new treatments for persistent negative symptoms of schizophrenia. Ongoing work with novel compounds and new formulations may assist in the translation of these advances into clinic-ready pharmacotherapies.Keywords
This publication has 45 references indexed in Scilit:
- Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of AntipsychoticNeuropsychopharmacology, 2005
- Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserinePsychiatry Research: Neuroimaging, 2005
- Sodium benzoate attenuates d-serine induced nephrotoxicity in the ratToxicology, 2004
- d-Serine-induced nephrotoxicity: possible interaction with tyrosine metabolismToxicology, 2004
- Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of actionMolecular Psychiatry, 2004
- Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site AgonistsNeuropsychopharmacology, 2003
- The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological studyPharmacology Biochemistry and Behavior, 2003
- Discovery and SAR of Org 24598—A Selective Glycine Uptake InhibitorBioorganic & Medicinal Chemistry Letters, 2001
- Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome studyJournal of Psychopharmacology, 2001
- Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptomsInternational Journal of Neuropsychopharmacology, 1999